Resource utility {#S1}
================

This human iPSC line is a useful tool for studies of disease phenotype and pathophysiology, and use as a cell-based disease model for drug development to treat patients with NPB.

Resource details {#S2}
================

Niemann-Pick disease type B (NPB) is a rare autosomal recessive, lysosomal storage disease that is caused by mutations in the *SMPD1* gene, leading to a deficiency in acid sphingomyelinase in the lysosome of patient cells. This deficiency leads to an accumulation of sphingomyelin in the lysosome, resulting in hepatosplenomegaly and other symptoms in NPB patients ([@R3]; [@R4]).

In this study, a human induced pluripotent stem cell (iPSC) line TRNDi004-I was established from dermal fibroblasts of a 1-year-old male patient ([Table 1](#T2){ref-type="table"}). The integration-free CytoTune-Sendai viral vector kit (A16517, Thermo Fisher Scientific) containing OCT 3/4, KLF4, SOX2, and c-MYC pluripotency transcription factors was used to transduce the patient fibroblasts using methods previously stated ([@R2]; [@R1]). Genetic analysis shows that this iPSC line carries a heterozygous gene mutation of p.L43_A44delLA in exon 1 of *SMPD1* ([Fig. 1B](#F1){ref-type="fig"}). The cells exhibit a classical embryonic stem cell morphology ([Fig. 1A](#F1){ref-type="fig"}) and carry a normal karyotype (46, XY), as confirmed by G-banding karyotype analysis ([Fig. 1D](#F1){ref-type="fig"}). Immunohistochemistry staining and flow cytometry analysis demonstrated high expression levels of major pluripotency protein markers of NANOG, SOX2, OCT4, SSEA4, and TRA-1--60 on those cells ([Fig. 1A](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}). Sendai virus (SeV) clearance was verified with reverse transcription polymerase chain reaction (RT-PCR) using SeV-specific primers with no virus present by passage 15 ([Fig. 1E](#F1){ref-type="fig"}). The iPSC line was not contaminated with mycoplasma ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}) and was authenticated using STR DNA analysis, which demonstrated matching genotype at all 18 loci examined (information available with the authors). Furthermore, the pluripotency of this iPSC line was confirmed by the teratoma formation experiment that exhibited its ability to differentiate into cells/tissues of all three germ layers (ectoderm, mesoderm and endoderm) *in vivo* ([Fig. 1F](#F1){ref-type="fig"}).

Materials and methods {#S3}
=====================

Cell culture {#S4}
------------

Patient skin fibroblasts were obtained from Coriell Cell Repositories (GM11097) and cultured in DMEM (Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin in a humidified incubator with 5% CO~2~ at 37 °C. TRNDi004-I iPSCs were cultured in StemFlex medium (Thermo Fisher Scientific) on Geltrex (Thermo Fisher Scientific)-coated plates. The cells were maintained at 5% CO~2~, 5% O~2~ at 37 °C and the cells were passaged with 0.5 mM ethylenediaminetetraacetic acid (EDTA) when colonies were approximately 70% confluent.

Reprogramming of human skin fibroblasts {#S5}
---------------------------------------

Fibroblast cells were reprogrammed into iPSCs using the integration-free CytoTune Sendai viral vector kit (A16517, Thermo Fisher Scientific) following the methods previously stated ([@R2]; [@R1]).

Immunocytochemistry staining {#S6}
----------------------------

For immunofluorescence staining, patient iPSCs were fixed with 4% paraformaldehyde for 30 min at RT, permeabilized with 0.3% Triton X-100 in Dulbecco's phosphate-buffered saline (DBPS) for 15 min, and washed with DPBS. Cells were blocked using Image-iT™ FX signal enhancer (Thermo Fisher Scientific) for 1 h and incubated with primary antibodies, including SOX2, OCT4, NANOG and SSEA4, overnight at 4 °C. Cells were then washed and incubated with corresponding secondary antibody conjugated with Alexa Fluor 488 or Alexa Fluor 594 for 1 h at room temperature (antibodies used are listed in [Table 2](#T3){ref-type="table"}). Cells were washed and stained with Hoechst 33342 for 15 min and imaged using an INCell Analyzer 2200 imaging system (GE Healthcare) with 20× objective lens and Texas Red, FITC and DAPI filter sets.

Genome analysis of variant in SMPD1 gene {#S7}
----------------------------------------

The genome analysis of variants in the *SMPD1* gene was conducted through Applied StemCell (Milpitas, CA, USA). Genomic DNA was extracted from iPSC line TRNDi004-I followed by PCR amplification using MyTaq™ Red Mix (Bioline, Taunton, MA). Amplifications were carried out using the following program: 95 °C, 2 min; 35 cycles of \[95 °C, 15 s; 60 °C, 15 s; 72 °C, elongation duration varies by amplificon size\], 72 °C, 5 min; 4 °C, indefinite. PCR products were subsequently sequenced by using Sanger sequencing analysis to identify potential mutations. The specific primers for gene amplification and sequencing are listed in [Table 2](#T3){ref-type="table"}. The heterozygous gene mutation of p.L43_A44delLA in exon 1 of *SMPD1* was further confirmed by Codex BioSolutions, Inc. (Gaithersburg, MD).

Flow cytometry analysis {#S8}
-----------------------

The iPSCs were harvested using TrypLE Express enzyme (Thermo Fisher Scientific). Cells were fixed with 4% paraformaldehyde for 10 min at room temperature and then washed with DPBS. Before fluorescence-activated cell sorting analysis, cells were permeabilized with 0.2% Tween-20 in DPBS for 10 min at room temperature and stained with fluorophore-conjugated antibodies for 1 h at 4 °C on a shaker. Relative fluorophore-conjugated animal nonimmune immunoglobulin was used as the negative control (antibodies and nonimmune immunoglobulin used are listed in [Table 2](#T3){ref-type="table"}). Cells were then analyzed on a BD AccuriC6 Flow Cytometry system (BD Biosciences).

G-banding karyotype {#S9}
-------------------

The G-banding karyotype analysis was performed at WiCell Research Institute (Madison, WI, USA). A total of 20 randomly selected metaphases were analyzed by G-banding.

Testing for Sendai reprogramming vector clearance {#S10}
-------------------------------------------------

Total RNA was isolated from iPSCs TRNDi004-I of passage 15 using RNeasy Plus Mini Kit (Qiagen). Human fibroblasts (Coriell Institute, GM05659), after infection with Sendai virus for 4 days, were used as a positive control. A total of 1 μg RNA/reaction was reverse transcribed with SuperScript™ III First-Strand Synthesis SuperMix kit, and PCR was performed using Platinum II Hot Start PCR Master Mix (Thermo Fischer Scientific) with the primers listed in [Table 2](#T3){ref-type="table"}. The products were then loaded into an *E*-Gel® 1.2% with SYBR Safe™ gel and run at 120 V electric field. Finally, the image was collected using G: Box Chemi-XX6 gel doc system from Syngene (Frederick, MD).

Short tandem repeat (STR) DNA profile analysis {#S11}
----------------------------------------------

NPB patient fibroblasts and iPSCs were sent to the John Hopkins University Genetic Resources Core Facility for STR DNA profile analysis using a Promega PowerPlex 18D Kit. The PCR product was electrophoresed on an ABI Prism® 3730xl Genetic Analyzer and data were analyzed using GeneMapper® v 4.0 software (Applied Biosystems).

Mycoplasma detection {#S12}
--------------------

Mycoplasma testing was performed and analyzed using the Lonza MycoAlert kit (Lonza), following the protocol from the company. (Ratio B/A \> 1.2 mycoplasma positive; 0.9--1.2 results ambiguous; \< 0.9 mycoplasma negative).

Teratoma formation assay {#S13}
------------------------

Patient iPSCs cultured in 6- well plates were dissociated with DPBS containing 0.5 mM EDTA and approximately 1 × 10^7^ dissociated cells were collected and re-suspended in 400 μl culture medium supplied with 25 mM HEPES (pH 7.4) and stored on ice. Then, 50% volume (200 μl) of cold Matrigel (354277, Corning) was added and mixed with the cells. The mixture was injected subcutaneously into NSG mice (JAX No. 005557) at 150 μl per injection site. Visible tumors were removed 6--8 weeks post injection that were immediately fixed in 10% Neutral Buffered Formalin. The fixed tumors were embedded in paraffin and stained with hematoxylin and eosin. Images were collected and analyzed using the NanoZoomer Digital Pathology software (Hamamatsu).
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![Characterization of TRNDi004-I iPSC line.\
**A)** Left: phase contrast imaging of TRNDi004-I colonies grown on Geltrex. Right: Representative immunofluorescent images of iPSCs positive for stem cell markers: SOX2, OCT4, NANOG, and SSEA4. Nucleus is labelled with Hoechst (blue). **B)** Detection of a heterozygous gene mutation of p.L43_A44delLA in the SMPD1 gene of iPSC TRNDi004-I. **C)** Flow cytometry analysis of pluripotency protein markers: TRA-1--60, NANOG and SSEA4. **D)** Cytogenetic analysis showing a normal karyotype (46, XY). **E)** RT-PCR verification for the clearance of the Sendai virus from reprogrammed cells. Sendai virus vector transduced fibroblasts were used as positive control. **F)** Pathological analysis of teratoma from TRNDi004-I iPSC, showing a normal ectodermal, mesodermal, and endodermal differentiation.](nihms-1530923-f0001){#F1}

###### 

Resource table

  --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Unique stem cell line identifier        TRNDi004-I
  Alternative name(s) of stem cell line   HT222I
  Institution                             National Institutes of Health National Center for Advancing Translational Sciences Bethesda, Maryland, USA
  Contact information of distributor      Dr. Wei Zheng <Wei.Zheng@nih.gov>
  Type of cell line                       iPSC
  Origin                                  Human
  Additional origin info                  Age: 1-year-old
                                          Sex: Male
                                          Ethnicity: N/A
  Cell source                             Skin dermal fibroblasts
  Clonality                               Clonal
  Method of reprogramming                 Integration-free Sendai viral vectors
  Genetic modification                    NO
  Type of modification                    N/A
  Associated disease                      Niemann-Pick disease type B (NPB)
  Gene/locus                              Gene: *SMPD1*
                                          Locus: 11p15.4
                                          Mutation: p. L43_A44delLA
  Method of modification                  N/A
  Name of transgene or resistance         N/A
  Inducible/constitutive system           N/A
  Date archived/stock date                2018
  Cell line repository/bank               N/A
  Ethical approval                        NIGMS Informed Consent Form was obtained from patient at time of sample submission. Confidentiality Certificate: CC-GM-15--004
  --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------

###### 

Characterization and validation.

  Classification                        Test                                   Result                                                                       Data
  ------------------------------------- -------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------
  Morphology                            Photography                            Normal                                                                       [Fig. 1](#F1){ref-type="fig"} Panel A
  Phenotype                             Immunocytochemistry                    SOX2, OCT4, NANOG, SSEA4                                                     [Fig. 1](#F1){ref-type="fig"} Panel A
                                        Flow cytometry                         TRA-1--60 (94.30%); NANOG (91.82%); SSEA4 (99.91%)                           [Fig. 1](#F1){ref-type="fig"} Panel C
  Genotype                              Karyotype (G-banding) and resolution   46XY Resolution: 500--550                                                    [Fig. 1](#F1){ref-type="fig"} Panel D
  Identity                              Microsatellite PCR (mPCR) OR           Not performed                                                                N/A
                                        STR analysis                           18 sites tested, all sites matched                                           Available from the authors
  Mutation analysis (If Applicable)     Sequencing                             Heterozygous mutation of *SMPD1*, p.L43_A44delLA                             [Fig. 1](#F1){ref-type="fig"} Panel B
                                        Southern Blot OR WGS                   N/A                                                                          N/A
  Microbiology and virology             Mycoplasma                             Mycoplasma testing by luminescence. Negative                                 [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}
  Differentiation potential             Teratoma formation                     Teratoma with three germlayers formation (ectoderm, mesoderm and endoderm)   [Fig. 1](#F1){ref-type="fig"} Panel F
  Donor screening (Optional)            HIV 1 + 2 Hepatitis B, Hepatitis C     N/A                                                                          N/A
  Genotype additional info (Optional)   Blood group genotyping                 N/A                                                                          N/A
                                        HLA tissue typing                      N/A                                                                          N/A

###### 

Reagents details.

  Antibodies used for immunocytochemistry/flow-cytometry                                                                                                                     
  -------------------------------------------------------- ------------------------------------------ ---------------------------------------------------------------------- -----------------------------------------------------------
  Pluripotency markers                                     Mouse anti-SOX2                            1:50                                                                   R & D Systems, Cat\# MAB2018, RRID: AB_358009
  Pluripotency markers                                     Rabbit anti-NANOG                          1:400                                                                  Cell Signaling Technology, Cat\# 4903, RRID: AB_10559205
  Pluripotency markers                                     Rabbit anti-OCT4                           1:400                                                                  Thermo Fisher, Cat\# A13998, RRID: AB_2534182
  Pluripotency markers                                     Mouse anti-SSEA4                           1:1000                                                                 Cell Signaling Technology, Cat\# 4755, RRID: AB_1264259
  Secondary antibodies                                     Donkey anti-Mouse IgG (Alexa Fluor 488)    1:400                                                                  Thermo Fisher, Cat\# A21202, RRID: AB_141607
  Secondary antibodies                                     Donkey anti-Rabbit IgG (Alexa Fluor 594)   1:400                                                                  Thermo Fisher, Cat\# A21207, RRID: AB_141637
  Flow cytometry antibodies                                Anti-Tra-1--60-DyLight 488                 1:50                                                                   Thermo Fisher, Cat\# MA1--023-D488X, RRID: AB_2536700
  Flow Cytometry Antibodies                                Anti-Nanog-Alexa Fluor 488                 1:50                                                                   Millipore, Cat\# FCABS352A4, RRID: AB_10807973
  Flow cytometry antibodies                                anti-SSEA-4-Alexa Fluor 488                1:50                                                                   Thermo Fisher, Cat\# 53--8843--41, RRID: AB_10597752
  Flow cytometry Antibodies                                Mouse-IgM-DyLight 488                      1:50                                                                   Thermo Fisher, Cat\# MA1--194-D488, RRID: AB_2536969
  Flow Cytometry antibodies                                Rabbit IgG-Alexa Fluor 488                 1:50                                                                   Cell Signaling Technology, Cat\# 4340S, RRID: AB_10694568
  Flow cytometry antibodies                                Mouse IgG3-FITC                            1:50                                                                   Thermo Fisher, Cat\# 11--4742--42, RRID: AB_2043894
                                                                                                                                                                             
  Primers                                                                                                                                                                    
                                                                                                                                                                             
                                                           Target                                     Forward/Reverse primer (5′−3′)                                         
                                                                                                                                                                             
  Sev specific primers (RT-PCR)                            Sev/181 bp                                 GGA TCA CTA GGT GAT ATC GAG C/ACC AGA CAA GAG TTT AAG AGA TAT GTA TC   
  Sev specific primers (RT-PCR)                            KOS/528 bp                                 ATG CAC CGC TAC GAC GTG AGC GC/ACC TTG ACA ATC CTG ATG TGG             
  Sev specific primers (RT-PCR)                            Klf4/410 bp                                TTC CTG CAT GCC AGA GGA GCC C/AAT GTA TCG AAG GTG CTC AA               
  Sev specific primers (RT-PCR)                            C-Myc/523 bp                               TAA CTG ACT AGC AGG CTT GTC G/TCC ACA TAC AGT CCT GGA TGA TGA TG       
  House-Keeping gene (RT-PCR)                              GAPDH/197 bp                               GGA GCG AGA TCC CTC CAA AAT/GGC TGT TGT CAT ACT TCT CAT GG             
  Targeted mutation analysis (PCR)                         SMPD1--1/559 bp                            GTC AGC CGA CTA CAG AGA AGG/TAG ATG CCA CCC TCT CCA TCA G              
  Targeted mutation analysis (PCR)                         SMPD1--2/454 bp                            CTG AAG GTG AGC ACT GAA GG/TGG TGA GAA ATC AGA GGC AG                  
  Targeted mutation analysis (PCR)                         SMPD1--3/457 bp                            ATC TGG AAG GCA AAG GTG TG/GTC AGT GAG GAA GAG GAT GC                  
  Targeted mutation analysis (PCR)                         SMPD1--4/576 bp                            TGG AAC ATC TCT TTG CCT ACT GTG/CGA TAA GTA CCT GAG GGT GC             
  Targeted mutation analysis (PCR)                         SMPD1--5/805 bp                            GCA CAC CTG TCA ATA GCT TCC CT/TGA AGG AGG GTG GCT GGA GAT             
  Targeted mutation analysis (PCR)                         SMPD1--6/164 bp                            CCT TTC TAC TCT TAT CTC CAG CCA C/GGG AAG ATG ACA TGG GAT GG           
  Targeted mutation analysis (PCR)                         SMPD1--7/443 bp                            ACC TTA TCC ATC CCA TGT CAT CTT CC/TCT CCT CGA TCC TCA GCA GC          
  Targeted mutation analysis (PCR)                         SMPD1--8/483 bp                            GTC TCC GCC TCA TCT CTC TC/ACT CAC CCT GTC CCT ATT CC                  
  Targeted mutation analysis (PCR)                         SMPD1--9/490 bp                            TCC TTA ATT CTC CCT ACT AGG TGC/CCC ACC AAC TCC AGG ATA AG             
  Targeted mutation analysis (PCR)                         SMPD1--10/533 bp                           CTG GCT GCT CAG TTC TTT GG/TGG TAG AGA AAC CAG AAG GTC                 
  Targeted mutation analysis (PCR)                         SMPD1--11/460 bp                           CAT ACC GCA CTG GCA GCT TC/CTC CAG GAA AGG AGA AGG TC                  
  Targeted mutation analysis (PCR)                         SMPD1--12/656 bp                           TGG CAG CTT CTC TAC AGG GC/TAA CAG ACT GGC AGC ATC AGG T               
